Stocktoria

Bausch & Lomb Corp BLCO

NYSE · stock · Ophthalmic Goods · website · IPO 2022-05-06 · LEI

Bausch & Lomb Corp (BLCO) earns a Piotroski F-score of 3/9 (weak financial health), with an Altman Z″ in the grey zone. It does not currently pay a dividend. FY2025 revenue was $5.1B at a -7.1% net margin.

Chart by TradingView
35/100
Stocktoria Quality Score · grade D
3/9
Piotroski F — financial health
1.24
Altman Z″ — distress risk · grey
Dividend yield · no dividend

Quality score trend · recomputed for each fiscal year

Piotroski F /9
4 2 3 3 2022202320242025
Altman Z″
2.47 1.69 1.45 1.24 2022202320242025

Each year's score is computed from that year's filing — a rising Piotroski F or Altman Z″ means improving financial health, a fall is worth a look.

$16.76 as of 2026-08-01 · +14.6% 1y
$14.63$18.3052-wk
Market cap USD$5.8B
Net margin 5y avg-3%
Return on equity 5y avg-2.4%
Beta0.57
Employees13,000

Analyst price target

$17.88 +6.7% vs last
consensus: buy · 12 analysts
target range $16.00 – $21.00 · median $18.00
2 strong buy · 3 buy · 7 hold · 1 strong sell
Recent analyst actions
DateFirmRating
2026-04-30Evercore ISI GroupIn-Line (main)
2026-04-06Evercore ISI GroupIn-Line (main)
2026-02-23HC Wainwright & Co.Buy (main)
2026-02-19CitigroupBuy (main)
2026-02-19BarclaysEqual-Weight (main)
2026-02-19StifelHold (main)

Wall Street analyst consensus — a sentiment gauge, not our scoring.

Revenue trend · last 5y · up

How it ranks in Manufacturing · percentile among 1957 companies

Piotroski Fstronger than 27%
Net marginstronger than 43%
Return on equitystronger than 52%
Revenue growthstronger than 54%

Percentile vs other Manufacturing companies we cover — e.g. “stronger than 90%” means only 10% score higher on that measure.

Piotroski F breakdown · 3/9 tests passed

Altman Z″ components · grey zone

ComponentValue
Working capital / assets0.075
Retained earnings / assets-0.066
EBIT / assets0.008
Equity / liabilities0.869

Sector peers · similar-size Manufacturing companies compare side by side →

TickerCompanyPiotroski FAltman Z″P / ERevenue growth
BLCOBausch & Lomb Corp3/91.24+6.5%
COOCOOPER COMPANIES, INC.6/94.9936.9+5.1%
EYENational Vision Holdings, Inc.7/90.8251+9%
WRBYWarby Parker Inc.5/9-0.22+13%
STAASTAAR SURGICAL CO1/94.46-23.7%
RXSTRxSight, Inc.2/95.56-3.9%
LUCYInnovative Eyewear Inc4/9

All Manufacturing companies →

About Bausch & Lomb Corp

Bausch + Lomb Corporation operates as an eye health company in the United States, Puerto Rico, China, France, Japan, Germany, the United Kingdom, Canada, Russia, Spain, Italy, Mexico, Poland, and internationally. It operates in three segments: Vision Care, Pharmaceuticals, and Surgical. The Vision Care segment provides contact lens that covers the spectrum of wearing modalities, including daily disposable and frequently replaced contact lenses; and contact lenses that are indicated for therapeutic use and provide optical correction during healing. It also offers contact lens care products, eye vitamins, mineral supplements, and over-the-counter eye drops that address various conditions, such as eye allergies, conjunctivitis, dry eye, and redness relief. The Pharmaceuticals segment offers proprietary and generic pharmaceutical products for post-operative treatments, as well as for the treatment of glaucoma, eye inflammation, ocular hypertension, dry eyes, and retinal diseases. The Surgical segment provides medical device equipment, consumables, and technologies for the treatment of cataracts, corneal, vitreous, and retinal eye conditions; and intraocular lenses and delivery systems, phacoemulsification equipment, and other surgical instruments and devices for cataract surgery. The company sells its products and services through direct sales forces and independent distributors. Bausch + Lomb Corporation was founded in 1853 and is headquartered in Vaughan, Canada. Bausch + Lomb Corporation operates as a subsidiary of Bausch Health Companies Inc.

FAQ

Is BLCO financially healthy?

Bausch & Lomb Corp's Piotroski F-score is 3/9 (8–9 is excellent, 0–3 weak), and its Altman Z″ distress score is in the grey zone.

Does BLCO pay a dividend?

No, Bausch & Lomb Corp does not currently pay a dividend.

How profitable is BLCO?

In FY2025, Bausch & Lomb Corp had a net margin of -7.1% and a return on equity of -5.5%.

What is the analyst price target for BLCO?

The average Wall-Street price target for Bausch & Lomb Corp is $17.88, about 6.7% above the recent price, from 12 analysts (consensus: buy).

Is BLCO a good stock to buy?

Stocktoria doesn't give buy or sell advice, but here is the data on Bausch & Lomb Corp: a Piotroski F-score of 3/9, an Altman Z″ in the grey zone. Weigh these quality and valuation signals against your own goals.

Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.